

# UC San Diego

## UC San Diego Previously Published Works

### Title

MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)

### Permalink

<https://escholarship.org/uc/item/4f33s5hg>

### Authors

David, Paula

Sinha, Saptarshi

Iqbal, Khizer

et al.

### Publication Date

2024-06-01

### DOI

10.1016/j.ebiom.2024.105136

Peer reviewed

# MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)



Paula David,<sup>a,b,c,p</sup> Saptarshi Sinha,<sup>d,p</sup> Khizer Iqbal,<sup>a,p</sup> Gabriele De Marco,<sup>b,e,f</sup> Sahar Taheri,<sup>g</sup> Ella McLaren,<sup>d</sup> Sheetal Maisuria,<sup>h</sup> Gururaj Arumugakani,<sup>h,i</sup> Zoe Ash,<sup>j</sup> Catrin Buckley,<sup>a</sup> Lauren Coles,<sup>a</sup> Chamila Hettiarachchi,<sup>e</sup> Emma Payne,<sup>h</sup> Sinisa Savic,<sup>b,f,k</sup> Gayle Smithson,<sup>e</sup> Maria Slade,<sup>e</sup> Rahul Shah,<sup>a</sup> Helena Marzo-Ortega,<sup>a,b,f</sup> Mansoor Keen,<sup>j</sup> Catherine Lawson,<sup>l</sup> Joanna Mclorinan,<sup>a</sup> Sharmin Nizam,<sup>e</sup> Hanu Reddy,<sup>m</sup> Omer Sharif,<sup>n</sup> Shabina Sultan,<sup>m</sup> Gui Tran,<sup>l</sup> Mark Wood,<sup>a</sup> Samuel Wood,<sup>a</sup> Pradipta Ghosh,<sup>d,o,\*\*</sup> and Dennis McGonagle<sup>a,b,\*</sup>



<sup>a</sup>Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom

<sup>b</sup>University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

<sup>c</sup>Internal Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

<sup>d</sup>Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA

<sup>e</sup>Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom

<sup>f</sup>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

<sup>g</sup>Department of Computer Science and Engineering, Jacob's School of Engineering, University of California San Diego, La Jolla, CA, 92093, USA

<sup>h</sup>Leeds Teaching Hospitals NHS Trust, Pathology, Leeds, United Kingdom

<sup>i</sup>University of Leeds, Immunology, Leeds, United Kingdom

<sup>j</sup>Bradford Teaching Hospitals NHS Foundation Trust, Rheumatology, Bradford, United Kingdom

<sup>k</sup>Department of Clinical Immunology and Allergy, Leeds Teaching Hospitals, NHS Trust, Leeds, UK

<sup>l</sup>Harrogate and District NHS Foundation Trust, Rheumatology, Harrogate, United Kingdom

<sup>m</sup>Airedale NHS Foundation Trust, Rheumatology, Steeton with Eastburn, United Kingdom

<sup>n</sup>Calderdale and Huddersfield NHS Foundation Trust, Rheumatology, Huddersfield and Halifax, United Kingdom

<sup>o</sup>Department of Medicine, School of Medicine, and Veterans Affairs Medical Center, University of University of California San Diego, La Jolla, CA, 92093, USA

## Summary

**Background** Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5<sup>+</sup>-DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 is an RNA sensor and a key pattern recognition receptor for the SARS-CoV-2 virus.

**Methods** This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between January 2018 and December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5<sup>+</sup>-DM outbreak.

**Findings** Sixty new anti-MDA5<sup>+</sup>, but not other MSAs surged between 2020 and 2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-CoV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 vaccines. 25/60 cases developed ILD which rapidly progressed with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong *IFIH1* (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and *IFIH1* strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8<sup>+</sup> T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The *IFIH1* rs1990760TT variant blunted such response.

eBioMedicine

2024;104: 105136

Published Online xxx

<https://doi.org/10.1016/j.ebiom.2024.105136>

1016/j.ebiom.2024.105136

105136

\*Corresponding author. Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom.

\*\*Corresponding author. Departments of Medicine and Cellular and Molecular Medicine, University of California San Diego, 9500 Gilman Drive (MC 0651), George E. Palade Bldg, Rm 232, 239, La Jolla, CA, 92093, USA.

E-mail addresses: [d.g.mcgonagle@leeds.ac.uk](mailto:d.g.mcgonagle@leeds.ac.uk) (D. McGonagle), [prghosh@ucsd.edu](mailto:prghosh@ucsd.edu) (P. Ghosh).

<sup>P</sup>These authors contributed equally as first author.

**Interpretation** A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-CoV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms.

**Funding** This work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes of Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists.

**Copyright** © 2024 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** Melanoma differentiation-associated protein-5 (MDA5); Interstitial lung disease (ILD); Autoimmune Raynauds; Autoimmune rashes; MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 (MIP-C); Coronavirus-19 (Covid-19)

#### Research in context

##### Evidence before this study

Case series and case reports of MDA5+ autoimmune disease emerged during the COVID-19 pandemic. MDA5+ dermatomyositis (DM) is a rare and intractable known pre-pandemic entity which is characterized by a high mortality due to rapid-progressive interstitial lung disease (ILD; in ~50–100% of the cases). Because MDA5 is a key sensor for viral RNA, and because ILDs are now a well-recognized entity in the aftermath of COVID-19, we explored a plausible link between coronavirus infection and such pathology.

##### Added value of this study

By following a large cohort of patients who developed **MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with the COVID-19 Pandemic (MIP-C)**, this study defines similarities and differences between MIP-C and MDA5+ disease. MIP-C occurred around times or followed high community SARS-CoV2 circulation and only 58% cases

had prior vaccination against SARS-CoV2. MIP-C had less ILD (~40%) and more Raynaud's and cutaneous manifestations. Despite these differences, bioinformatic analyses confirmed the shared immunophenotypes between the two as drivers of ILD, but both very distinct than idiopathic pulmonary fibrosis (IPF).

##### Implications of all the available evidence

Our findings offer insights into a distinct form of MDA5+ disease in the COVID-19 era that we term MIP-C. A relationship between circulating SARS-CoV-2 viral waves, the potential risk of developing this entity after mild infections, and its contemporaneousness with vaccination suggests the potential emergence of a distinct but rare form of MDA5+ DM, with distinct features to pre-pandemic era MDA5+ disease. Awareness and follow up of MIP-C is vital to ascertain whether it will evolve into the typical adult form of MDA5 with much higher rates of lung disease.

## Introduction

Dermatomyositis (DM) is a systemic autoimmune disease characterized by muscle and skin inflammation and potentially fatal-internal organ involvement, typically interstitial lung disease (ILD) leading to progressive pulmonary fibrosis. The first autoantibody defined in DM was anti-Mi-2, which targets the Mi-2 nuclear antigen.<sup>1</sup> Since then, many myositis-specific and related autoantibodies (MSA) emerged, often linked to different clinical phenotype patterns and different MHC-II associations that further underpin the veracity of the autoimmunity concept in DM.<sup>2–7</sup>

One of the well-recognised clinical phenotype of DM is clinically amyopathic dermatomyositis (CADM) that is associated with rapidly progressive ILD and is attributed to the Retinoic acid-inducible gene 1 (RIG-1)-like receptor family gene, *IFIH1*, which encodes the protein

Melanoma differentiation-associated protein-5 (MDA5).<sup>8</sup> Most MDA5+ cases predating the COVID-19 pandemic reported significant ILD but a relative lack of myositis or the classical DM heliotropic rash; instead, they showed cutaneous phenotypes including skin ulceration and tender palmar papules.<sup>9–11</sup>

Here we report a surge in the rate of anti-MDA5 positivity testing in our region (Yorkshire) in the second year of the COVID-19 pandemic, which was notable because this entity is relatively rare in the UK. This was intriguing because MDA5 is a RIG-1 helicase<sup>12</sup> tasked as an RNA sensor and is a key pattern recognition receptor for the contemporary SARS-CoV-2 virus.<sup>13</sup> Variants of the MDA5 protein-coding gene, *IFIH1* (rs1990760 TT) have recently been shown to confer protection in COVID-19 infections and experienced better outcomes.<sup>14</sup>

In this retrospective study, we explored the phenotypes and epidemiological factors associated with the cluster of MDA5<sup>+</sup>-related disease at our centre which provides autoantibody testing for a 3.6 million-large population (Fig. 1-Steps 1–2). We describe this phenomenon as MDA5 autoimmunity with interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C) that reflects the different epidemiology and clinical patterns reported herein compared to previously defined MDA5 related autoimmunity. We also leveraged transcriptomic datasets to explore putative mechanisms of this emergent MDA5-associated disease in the setting of SARS-CoV-2 infection (Fig. 1-Step 3). Specifically, as post COVID pneumonia is associated with pulmonary fibrosis, we leveraged datasets to compare acute COVID-19 lung disease, autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5<sup>+</sup>-DM outbreak. Finally, we presented a working model that links severity of anti-viral cytokine response to *IFIH1* induction and genetics and ultimately, to the distinct immunophenotype specific for MSA-associated progressive ILD (Fig. 1-Step 4). These findings provide insights into the observed surge in anti-MDA5 positivity during the COVID-19 pandemic and the potential role of RNA viruses in rapidly progressive ILD and other autoimmune conditions.

## Methods

### Study design

The Leeds Teaching Hospitals NHS Trust serves as an immunology laboratory reference for the wider Yorkshire region of the UK. We audited the increased anti-MDA5 positivity in relationship to other MSA (Euroimmun line immunoassay (LIA) ©) that included MDA5<sup>+</sup> cases. This was based on both increased rate of anti-MDA5 related immunology reporting and multiple physicians seeing MDA5 related disease for the first time, combined with emergent literature reporting COVID-19 era anti-MDA5-related disease.<sup>2–5,15–32</sup> We collected data on the number of MDA5+ tests per year between January 2018 and December 2022. The clinical notes review focused on patterns of symptomatic MDA5 disease (including degree of ILD); muscle or other organs involvement, therapy, therapy responses and survival data.

We also leveraged Public Health England (PHE) data on SARS-CoV-2 monthly positivity rates in the Yorkshire region. We also evaluated data on lung involvement and concomitant SARS-CoV-2 infection, recent SARS-CoV-2 infection or recent SARS-CoV-2 vaccination or both infection and vaccination by searching for confirmed PCR positivity for infection or confirmation of vaccination status including number of vaccines administered as gleaned from “NHS spine” system, a system that supports the IT infrastructure for health and social care for England,

joining together over 44,000 healthcare systems in 26,000 organizations.<sup>33</sup>

### Antibodies analysed

Myositis-specific and related antibodies are analysed in our practice by using the Euroimmun line immunoassay (LIA) that includes the 16 following antigen blot: Mi-2 alpha, Mi-2 beta, TIF1g, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52, represented in Fig. 2A). The clinical specificity of this immunoassay to detect myositis-specific antibodies is known to range between 94.2% and 99.9%.<sup>34</sup>

The Euroimmun LIA provides a semi-quantitative quantification of titers according to intensity of incubated strips. Titers of MDA5 were considered according to the manufacturer’s grading system, where grade 1+ corresponds to intensity readings between 15 and 20, indicative of a low titer; grade 2+ corresponds to intensity readings between 20 and 40, suggestive of a moderate titer; and grade 3+ corresponds to intensity readings exceeding 40, indicating a high titer.

ANA testing was performed by indirect immunofluorescence using EUROIMMUN Hep2 slides.


### Statistical analysis

A descriptive analysis was performed to evaluate the MDA5+ cohort. Subsequently, univariate analysis was conducted to compare individuals with and without interstitial lung disease (ILD). The t-test was applied to variables demonstrating a normal distribution, while the Mann–Whitney U test was utilized for variables that violate the normality assumption. Chi-square ( $\chi^2$ ) was employed for analyzing categorical variables. Fisher’s exact test was utilized when the expected count was less than 5 in more than 20% of the cells. Statistical significance was considered when the p-value was below 0.05. SPSS software v27 was used to conduct the statistical analysis.


### Computational analyses

#### Transcriptomic datasets and data analyses

To explore potential mechanistic links between COVID infection and lung disease we analyzed several publicly available datasets (COVID-19, n = 240; ILD, n = 316; viral pneumonitis, n = 1038), a complete catalog of which is presented in Supplemental Information 1). To decipher which immunophenotype is induced in the setting of COVID-19, previously validated lung or PBMC-based gene signatures from distinct lung diseases were used: (i) idiopathic pulmonary fibrosis (IPF); (ii) hypersensitivity pneumonitis (HP); (iii) systemic autoimmune rheumatic diseases (SARDs) such as systemic sclerosis and MDA5<sup>+</sup>-DM; and (iv) well-defined signatures of so called “AT2 cytopathies”, i.e., ER stress, stem cell dysfunction, senescence, and telomere shortening, which have been implicated in driving fibrotic lung disease after diffuse alveolar injury, as in



**Fig. 1: Study Motivation, Design and Major Findings:** Schematic summarizes the retrospective study design and motivation (Step 1), and the phenotypical and epidemiological features observed in our cohort (Step 2). It also highlights the analyses of diverse transcriptomics datasets (Step 3) which were carried out to interrogate how COVID-19 infection interacts with *IFIH1* gene (encodes MDA5) and disease risk signatures for the development of interstitial pneumonitis of various types. Finally, we summarize findings and propose a working model linking epidemiologic findings to the insights drawn from transcriptomic analyses.



**Fig. 2: Rate of MDA5+ testing 2018 to 2022.** **A.** Heatmap (top) shows the fold change in MDA5+ for each of the tested muscle-specific auto-antibodies (MSAs), including anti-MDA5 (using Euroimmun immunoblot©). Table (bottom) provides the actual patient numbers. **B** and **C.** Graphs display the overlay of newly detected anti-MDA5 positivity (blue; A-B) with either total COVID-19 cases (red; A) or the rate of new vaccination (yellow; B) that were reported in the Yorkshire and Humber regions since Jan 2021 to Dec 2022. The COVID-19 case rates and vaccination rates were obtained from the [UK.gov](https://coronavirus.data.gov.uk/) database (<https://coronavirus.data.gov.uk/>). Red arrowheads denote the four waves of COVID-19 cases.

the setting of severe COVID-19<sup>35</sup> and IPF<sup>36</sup>). All gene signatures used in this work are presented in an excel sheet, alongside the original source articles ([Supplemental Information 2](#)).

*Single cell RNA sequencing analysis*

Single Cell RNASeq data from GSE145926 was downloaded from Gene Expression Omnibus (GEO) in the HDF5 Feature Barcode Matrix Format. The filtered barcode data matrix was processed using Seurat v3 R package. B cells (CD19, MS4A1, CD79A), T cells (CD3D, CD3E, CD3G), CD4 T cells (CCR7, CD4, IL7R, FOXP3, IL2RA), CD8 T cells (CD8A, CD8B), Natural killer cells (KLRF1), Macrophages, Monocytes and DCs (TYROBP, FCER1G), Epithelial (SFTPA1, SFTPB, AGER, AQP4, SFTPC, SCGB3A2, KRT5, CYP2F1, CCDC153, TPPP3) cells were identified using relevant gene markers using SCINA algorithm.

Several publicly available microarrays and RNASeq databases were downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) server. Gene expression summarization was performed by normalizing Affymetrix platforms by RMA (Robust Multichip Average) and RNASeq platforms by computing TPM (Transcripts Per Millions) values whenever normalized data were not available in GEO. We used log<sub>2</sub> (TPM + 1) as the final gene expression value for analyses. GEO accession numbers are reported in figures and text. A catalog of all datasets analyzed in this work can be found in [Supplemental Information 1](#).

*Gene expression analyses*

The expression levels of all genes in these datasets were converted to binary values (high or low) using the *StepMiner* algorithm<sup>37</sup> which uses an adaptive regression scheme to verify the best possible up and down steps based on sum-of-square errors. The steps are placed between data points at the sharpest change between expression levels, which gives us the information about threshold of the gene expression-switching event. To fit a step function, the algorithm evaluates all possible steps for each position and computes the average of the values on both sides of a step for the constant segments. An adaptive regression scheme is used that chooses the step positions that minimize the square error with the fitted data. Finally, a regression test statistic is computed as follows:

$$F \text{ stat} = \frac{\sum_{i=1}^n (\hat{X}_i - \bar{X})^2 / (m - 1)}{\sum_{i=1}^n (X_i - \hat{X}_i)^2 / (n - m)}$$

where  $X_i$  for  $i = 1$  to  $n$  are the values,  $\hat{X}_i$  for  $i = 1$  to  $n$  are fitted values.  $M$  is the degrees of freedom used for

the adaptive regression analysis.  $\bar{X}$  is the average of all the values:

$$\bar{X} = \frac{1}{n} * \sum_{j=1}^n X_j$$

For a step position at  $k$ , the fitted values  $\hat{X}_i$  are computed by using

$$\frac{1}{k} * \sum_{j=1}^n X_j$$

for  $i = 1$  to  $k$  and

$$\frac{1}{(n - k)} * \sum_{j=k+1}^n X_j$$

for  $i = k + 1$  to  $n$ .

Gene expression values were normalized according to a modified Z-score approach centered around *StepMiner* threshold (SThr) (formula = (expr - SThr) / 3\*stddev). The normalized expression values for every genes were added together to create the final score for the gene signature. The samples were ordered based on the final signature score. Classification of sample categories using this ordering is measured by ROC-AUC (Receiver Operating Characteristics Area Under The Curve) values. Welch's Two Sample t-test (unpaired, unequal variance (equal\_var = False), and unequal sample size) parameters were used to compare the differential signature score in different sample categories. Violin plots are created using python seaborn package version 0.10.1. Differentially expressed genes are identified using DESeq2 package in R.

*Correlation plot*

*StepMiner* normalized composite score of gene signatures were plotted against each other for all the patients. For each two signatures, linear least-squares regression has been obtained using SciPy LLS model (scipy.stats.linregress). R<sup>2</sup> and p-value for each pair of signatures are plotted as heatmap using seaborn (seaborn.heatmap) package. Confidence interval has been calculated using seaborn lmlot package and indicated as shaded area around the regression line.

*Multivariate analyses*

To assess which factor(s) may influence MDA5 induction upon exposure to SARS-CoV2, multivariate regression has been performed on the bulk sequence COVID-19 PBMC datasets (GSE233626 [updated with additional variables from GSE168400] and GSE233627 [updated with additional variables from GSE177025]). Multivariate analysis of GSE233626 models the degree of *IFIH1* induction in samples (base variable) as a linear combination of sex, age, ventilation, hypoxemia with/

without genotype. Multivariate analysis of GSE233627 also models the degree of *IFIH1* induction in samples (base variable) as a linear combination of the same variables as above, and an additional variable—that of treatment with systemic corticosteroids. Here, the statsmodels module from python has been used to perform Ordinary least-squares (OLS) regression analysis of each of the variables. The choice of these datasets was driven by the criteria that they are high quality datasets with maximal unique patient samples. The p-value for each term tests the null hypothesis that the coefficient is equal to zero (no effect).

#### Data and code availability

All codes and datasets used in this work can be found at [https://github.com/sinha7290/COVID\\_mda5](https://github.com/sinha7290/COVID_mda5).

#### Ethics statement

This study was reported according to the “CAse REports” (CARE) guidelines [<https://www.care-statement.org/>]. All participants recruited granted verbal or written consent to the local treating physicians for the use of their anonymized data. This was an approved retrospective audit of service delivery at our institution, and a formal Institutional Research Board (IRB) approval was not needed.

#### Role of funders

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Results

### MDA5 positivity between 2018 and 2022

Between January 2018 and December 2019, 6 new MDA5<sup>+</sup> cases were identified, representing 1.2% and 0.4% MSA immunoblot positivity in the respective years (Fig. 2A). However, commencing in 2021, after the second UK SARS-CoV-2 infection wave, we noted an increase in new MDA5<sup>+</sup> cases (Fig. 2). The total numbers of new cases were 9, 35 and 16 in 2020, 2021 and 2022 respectively (Fig. 2A). Irrespective of the fact that MSA requisitions requests approximately doubled during the same period of time, an increased rate of MDA5 positivity was evident, rising from 1.2% in 2018 and 0.4% in 2019 to 2.2% in 2020, 4.8% in 2021 and decreasing to 1.7% in 2022. The MDA5 positivity rate was significantly different when comparing pre-Covid19 period (2018–2019) to post Covid-19 period (2020–2022), 6/844 (0.7%) vs 60/2098 (2.9%),  $\chi^2$  test p-value <0.001. The other MSAs did not exhibit this striking pattern of increase (Fig. 2A-top).

### Clinical features of the 60 new MDA5 positive cases

Thirty-two/60 (53.3%) were of white ethnic background [either British or other still classified as white, according

to 2021 UK census methodology<sup>38</sup>]. Three/60 (5%) were of Asian/Asian British (all of these Indian/Pakistani) background; 2 (3.3%) were of Black Caribbean and 1 (1.6%) of Black African ethnic background and 4 (6.6%) were considered “any other ethnic group”. Four patient was of other Asian background (not Chinese) with no ethnicity data for 14/60 (23.3%) patients.

All 60 patients experienced some features consistent with an autoimmune disease, their average age was 56.17 years (median 56; standard deviation 19.9; absolute range 9–90; inter-quartile range 43.75–71.25) and 36/60 (60%) were female. Of the 60 patients, 25 (41.6%) developed ILD with a mean age 60.28 years; median 66; standard deviation 18.56; absolute range 12–90; and inter-quartile range 51–73. Twelve/25 (48%) were females. Almost half of this subgroup (12/25, 48%) rapidly progressed and 8/25 (32%) of them died. By contrast, just one fatality was observed in the 35 patients who did not develop ILD (sepsis-related). Out of 4 new paediatric patients in this series, none were fatal and none were vaccinated against SARS-CoV2.

The 35 patients in non-ILD group had a mean age of 53.23 years (median 54; standard deviation 20.6; absolute range 9–89; inter-quartile range 40–69). 24/35 (68.6%) were females; 4/60 (6.6%) were <18 years old. Although the non-ILD subgroup was younger than their ILD counterparts (Table 1), this difference was not statistically significant (Student T test p-value = 0.179). The two subgroups did not differ in terms of sex representation (Fisher’s exact test p-value 0.120).

The main indication for requesting MSA testing in the ILD subgroup was dyspnoea with and without associated myositic/DM features (Table 1, and Supplemental Table S1). The main indication for performing such testing in the non-ILD subgroup was cutaneous manifestations of DM, with or without muscle pain and weakness or scleroderma-like clinical features, as well as proximal myopathy, defined as bilateral proximal muscle weakness in lower or upper limbs as determined by the examining rheumatologist but without the use of an ordinal score for power (Table 1 and Supplemental Table S2). There was one case of confirmed myocarditis. The creatine kinase (CK) at baseline was available for 50/60 (83.3%) patients and its average was 811.78 units per liter (U/L), however, the median was 90.5 U/L in keeping with CADM phenotype (IQR 56.75–199); there was no statistically significant difference between ILD and non-ILD groups (median 78 vs 115, respectively Mann-whitney U test p value of 0.186). Of 35 non-ILD cases, at least 9 (missing data on imaging for 9/35 patients) had muscle MRI, of them 5 were compatible with myositis. Details of therapy are shown for each case in Supplemental Tables S1 and S2.



	ILD (n = 25)	nILD (n = 35)
<b>Females, n (%)</b>	12 (48%)	24 (68.6%)
<b>Age in years, mean (standard deviation)</b>	60.28, (18.56)	53.23, (20.6)
<b>Ethnic groups, n (%)</b>		
White	12 (48%)	20 (57%)
Asian/Asian British	3 (12%)	0 (0%)
Black Caribbean	0 (0%)	2 (6%)
Black African	0 (0%)	1 (3%)
Any other	2 (8%)	6 (17%)
Not available	8 (32%)	6 (17%)
<b>Indication for antibody testing</b>		
Dyspnoea (isolated), n (%)	17 (68%)	0 (0%)
Dyspnoea clinically predominant, with associated myositis/dermatomyositis features, n (%)	5 (20%)	0 (0%)
Myositis/dermatomyositis features clinically predominant, with dyspnoea, n (%)	1 (4%)	0 (0%)
Myositis without dermatologic features or dyspnoea, n (%)	0 (0%)	9 (25.7%)
Dermato-myositis-like clinical features, without dyspnoea, n (%)	2 (8%)	10 (28.6%)
Scleroderma-like clinical features, without dyspnoea, n (%)	0 (0%)	8 (22.85%)
Mixed/non-specific clinical features, n (%)	0 (0%)	8 (22.85%)
<b>Autoimmune serology</b>		
ANA IIF positive	15 (60%)	21 (60%)
ANA IIF negative	10 (40%)	14 (40%)
<b>Myositis-associated autoantibodies (n of people with, apart from MDA5)</b>	15 (60%)	21 (60%)
Anti-SAE1	7 (28%)	5 (14.3%)
Anti-Ro52	4 (16%)	9 (25.7%)
Anti-PMScl100	2 (8%)	2 (5.7%)
Others	5 (20%) <sup>a</sup>	13 (37.1%) <sup>c</sup>
<b>Clinical Features (other than ILD)</b>		
Cutaneous	8 (2%)	10 (28.6%)
Cardiac	0 (0%)	1 (2.9%)
Mechanic's hands	4 (16%)	1 (2.9%)
Synovitis	5 (20%)	15 (39.5%)
Raynaud's phenomenon	3 (12%)	17 (48.6%)
Proximal myopathy	3 (12%)	14 (40%)
<b>Treatment Outcomes</b>		
Response to treatment	5 (20%) <sup>b</sup>	11 (31.4%) <sup>d</sup>
Mortality	8 (32%)	1 (2.85%) <sup>e</sup>
Progressive lung involvement but alive	4 (16%)	0 (0%)
<b>Relationship between MDA5 and COVID-19 Infection/Vaccination</b>		
Infection preceding MDA5 positivity	4 (16%)	4 (11.4%)
Infection after MDA5 positivity	4 (16%)	3 (8.6%)
No known infection	17 (68%)	28 (80%)
Vaccination preceding MDA5 positivity	14 (56%)	22 (62.9%)
Vaccination after MDA5 positivity	6 (24%)	7 (20%)
No vaccination	5 (20%)	6 (17.1%)

MDA5, Melanoma Differentiation-Associated protein 5; ILD, Interstitial Lung Disease; ANA, Anti-Nuclear Autoantibodies; IIF, Indirect Immuno-fluorescence; COVID-19, Coronavirus disease 2019 (COVID-19), a contagious disease caused by the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). <sup>a</sup>Some simultaneously with above and between them, anti-PL7 (n = 2), anti-SRP (n = 2), anti-TIF1 (n = 1), anti-PL12 (n = 1), anti-MI-2-alpha (n = 1), anti-PMScl70 (n = 1). <sup>b</sup>Data not available on treatment 1 subjects, 7 were just under observation, with stable disease and 2 died before receiving treatment. <sup>c</sup>Some simultaneously with above and between them, anti-PL7 (n = 4), anti-TIF1 (n = 1), anti-mi-2-alpha (n = 1), anti-mi2-beta (n = 1) antiPMScl75 (n = 5), anti PScI70 (n = 1), anti-NPX2 (n = 5), anti-ku (n = 4), Anti-TH-to (n = 1), anti-RS (n = 1), Anti-OJ (n = 2), anti-EJ (n = 2) and anti-MTIF-gamma 2 (n = 2), anti-MPL122 (n = 1). <sup>d</sup>6 of patients had no available data regarding treatment, and 12 were at least stable without treatment (on observation), those were not included. <sup>e</sup>Pneumonia infection and sepsis.

**Table 1: MDA5+ Disease split up into ILD and non ILD cases.**

### MDA5 positive ILD outcomes

As expected the prognosis was poorer in the 25 patients in the ILD patients. Chest CT was available in 24/25 cases, which demonstrated fibrosis and associated ground glass changes in 6/25 (24%) cases; fibrotic changes only in 8/25 cases (32%); ground glass changes only in 9/25 (36%) cases; ground glass changes with pneumomediastinum in 1 case (4%). In keeping with the MDA5 phenotype, 8/25 (32%) patients progressed, most rapidly, and died despite intensive therapy; 4/25 (16%) developed progressive lung disease; 12/25 (48%) stabilised with or without specific therapy. There is one patient with no available data regarding response to treatment. There was no evidence of myocarditis in this subset and mortality was due to pulmonary disease (Supplemental Table S1). The only patient of paediatric age in this group remains stable.

### Non-ILD MDA5 positive disease

All MDA5<sup>+</sup> cases had some clinical features of autoimmune connective tissue disease, including cutaneous manifestations of DM or Raynaud's phenomenon (Table 1 and Supplemental Table S2). More patients in the non-ILD subgroup developed cutaneous rash (10/35, 28.6%) and Raynaud's phenomenon (17/35, 48.6%), sometimes both, and proximal myopathy (14/35, 4%) with only 1/35 (2/8%) developing "mechanic's hands" (Supplemental Table S2).

### Autoantibody testing

Thirty-six of 60 (60%) were ANA positive. There was no difference in ANA positivity between the ILD subgroup and the non-ILD subgroup (15/25 and 21/35, respectively—60% in both groups). Fourteen of 36 (39%) of ANA + patients were only weakly positive, 6/14 (43%) in the ILD group, and 8/14 (57%) in the non-ILD group. Regarding the ANA pattern, 18/36 (50%) were speckled, 13/36 (36%) were homogeneous, 3/36 (8%) were nucleolar and 1/36 (3%) were centromere and 1/36 (3%) were undefined. Within the non-ILD group, the majority of ANA + patients had a speckled pattern (13/21, 62%), 4/21 (19%) had a homogeneous pattern, 3/21 (14%) had a nucleolar pattern, and 1/21 (5%) had a centromere pattern. In the ILD group, the most common pattern was homogeneous (9/15, 60%), followed by 5/15 (33%) with a speckled pattern and 1/15 (7%), undefined.

Regarding anti-MDA5 titers, 9 out of 60 samples lacked available antibody semi-quantitative evaluation. Among the 51 samples with available titers, 28 out of 51 (55%) exhibited low antibody titers, 10 out of 51 (20%) showed moderate titers, and 13 out of 51 (26%) displayed high titers. Within ILD subgroup, 21 out of 25 (84%) had available semi-quantitative evaluation, with 8 out of 21 (38%) showing high titers, 2 out of 21 (9.5%) moderate titers, and 11 out of 21 (52.5%) low titers. Conversely, in the non-ILD group, 5 out of 35 samples

(14%) lacked available titers. Among the 30 available samples, 5 (16%) exhibited high titers, 8 (27%) showed moderate titers, and 17 (57%) displayed low titers. From the 8 ILD patients that rapidly progressed to death, 4 (50%) had high anti-MDA5 titres, no documented moderate titers, 3 (37.5%) low titer, and 1/8 (12.5%) the titer was unavailable. Only 1/3 of the ones who progressed rapidly and died despite of low anti-MDA5 titers had other myositis-associated antibodies, namely the anti-small ubiquitin-like modifier-1 (SAE-1).

In both subgroups SAE1 and Ro-52 were the auto-antibodies most often positive concomitantly to the anti-MDA5. 15/25 (60%) patients in the ILD subgroup had additional MSA antibodies as compared to 21/35 (60%) in the non-ILD subgroup ( $\chi^2$  test p-value = 0.930). 4/8 (50%) of patients who died in ILD subgroup had additional MSA antibodies, being SAE-1 MSA the most common, evident in 3/44/25 (16%) of ILD patients had both MDA5 and anti-Ro52, the latter of which is also known to be an ILD biomarker.<sup>39</sup>

### Relationship to COVID-19 infection or vaccination

In lieu of patient autoimmune symptoms and signs, MDA5<sup>+</sup> testing emerged only after the second and third SARS-CoV-2 wave in the Yorkshire region (Fig. 2B). Also, the highest rate of MDA5 positivity did occur during higher community SARS-CoV-2 positivity during 2021 but the highest rate of SARS-CoV-2 circulation was not followed by an immediate increased MDA5<sup>+</sup> testing (Fig. 2B). 8/60 (13.3%) had confirmed COVID-19 before anti-MDA5<sup>+</sup> test performed, and 7/60 (28.3%) were infected after the diagnosis, with 2 of them flaring during the infection. Overall, 15/60 (25%) had confirmed SARS-CoV-2 infection with only 8/25 (32%) positive in the ILD subgroup and 7/35 (20%) in the non-ILD subgroup.

As for vaccinations, the overall uptake of SARS-CoV-2 vaccination in the UK and Yorkshire region was 90% and we saw a strong overlap between vaccination timing in 2021 and the surge in MDA5<sup>+</sup> disease (Fig. 2C) but such a close link with monthly confirmed infections was lacking (Fig. 2B and C). 49/60 (81.6%) cases had documented evidence of SARS-CoV-2 vaccination; 20/25 (80%) in the ILD subgroup and 29/35 (82.8%) in non-ILD subgroup. 36/60 (60%) cases were vaccinated before anti-MDA5 positivity, 14/60 (23.3%) were vaccinated after, of which 2/14 (14.2%) had a disease flare. The 49 patients vaccinated received either RNA or DNA-based or a combination of both of them in different periods of times. 11/60 (18.3%)—5/25 (20%) ILD and 6/35 (17.1%) non-ILD—were not vaccinated at any point. In the ILD group, 14/25 (56%) were vaccinated preceding the MDA5<sup>+</sup> test, while in the non-ILD group 22/35 (62.9%) ( $\chi^2$  test p-value = 0.271).

Accordingly, most of the MDA5<sup>+</sup> cases had either confirmed infection or confirmed SARS-CoV-2 vaccination. All the 4 patients of paediatric age, were not

vaccinated (all of these developed MDA5 positivity after the pandemic started). Time-relationship to vaccine and infection for each individual is summarized in [Supplemental Tables S1 and S2](#).

### COVID-19 lungs show induction of MDA5 (*IFIH1*) gene and signatures of SARD-related ILD

We leveraged available transcriptomic datasets to explore potential mechanisms of MDA5+ disease in the setting of COVID-19. Analysis of bronchoalveolar lavage fluid from COVID-19 lungs by single cell RNA sequencing (scSeq; [Fig. 3A](#)) confirmed that *IFIH1* is induced significantly in diverse cells of the lavage fluid ([Fig. 3B](#); *arrow, bubble plot*), alongside the robust induction of a set of several previously validated signatures ([Fig. 3B](#)).

- (i) an intense IL-15-centric type 1 interferon (IFN) response, a.k.a, the Viral Pandemic (ViP) and its subset, severe(s)ViP signatures that was identified and rigorously validated using machine learning (on ~45,000 samples) which capture the ‘invariant’ host response, i.e., the shared fundamental nature of the host immune response induced by all viral pandemics, including COVID-19<sup>40</sup>;
- (ii) a COVID-19 lung signature<sup>41</sup>;
- (iii) a set of 3 signatures indicative of alveolar type two (AT2) cytopathies in fibrotic lung disease, i.e., (a) damage associated transient progenitor (DATP),<sup>42</sup> a distinct AT2 lineage that is a central feature of idiopathic pulmonary fibrosis (IPF)<sup>42–44</sup>; (b) AT2-senescence signature<sup>45</sup>; and (c) Telomerase dysfunction signature, which was derived from aging telomerase knockout (*Terc*<sup>-/-</sup>) mice.<sup>46</sup> Lung epithelial signatures of IPF were also induced ([Fig. 3B](#)), most consistently in the epithelium. However, gene signatures previously reported in ILDs that are related to SARDs [which include systemic sclerosis (SSc), DM, polymyositis (PM), rheumatoid arthritis (RA), primary Sjögren’s syndrome] were induced in a wide variety of cell types ([Fig. 3B](#)).

When exosome vesicles isolated from the serum of COVID-19 patients during various phases of the disease were applied to 2D cultures of lung or liver epithelial cells (see [Fig. 3C and D](#)), *IFIH1* (see [Fig. 3E and F](#); *arrows*) and gene signatures of AT2 cytopathies and autoimmune ILD were induced significantly and specifically in the lung, but not liver cells. Consistent with its role as an innate immune sensor of RNA viruses, the serum from the disease phase when viral RNA is detectable (S2 phase) triggered a significant induction in *IFIH1* and autoimmune-ILD signature (but not IPF) ([Fig. 3C](#)). We conclude that both *IFIH1* and autoimmune-ILD signatures were induced *in vivo* and *in vitro* upon exposure to viral RNA.

### Expression of MDA5 (*IFIH1*) gene and signatures of autoimmune ILD in COVID-19 PBMCs

The observed induction of *IFIH1* in the immune cells within the lungs warranted a similar analysis of peripheral blood mononuclear cells (PBMCs) from acute and convalescent COVID-19 subjects, using a set of gene signatures that were previously validated in immune cells (enlisted in [Fig. 4A](#)). We prioritized a dataset that also included the information on the *IFIH1* genotype rs1990760 which has recently been shown to impact the degree of inflammatory response and outcomes in COVID-19.<sup>14</sup> *IFIH1* induction tightly and positively correlated with type 1 IFNs ([Fig. 4B](#); ViP), an *ISG15*<sup>+</sup> *CD8*<sup>+</sup> cytotoxic T-cell signature that was found to be associated with risk of progressive ILD in the setting of MDA5 autoimmunity<sup>47</sup> ([Fig. 4B](#); anti-MDA5-ILD) and a distinctive IFN response that is specific for anti-MDA5+ DM ([Fig. 4B](#); anti-MDA5-DM IFNs). The rs1990760 TT variant that was found to be protective, showed a clear pattern in each comparison tested; two clear groups were observed in each comparison ([Fig. 4C](#)).


Unlike autoimmune ILDs, the IPF-related ILDs are known to have a completely distinct immunopathogenesis. We next leveraged a 52-gene PBMC-based IPF signature that was previously discovered<sup>48</sup> and subsequently validated as a predictor of IPF progression in a prospective multicenter study.<sup>49</sup> The expression of *IFIH1* negatively correlated with the 52-gene PBMC-based IPF signature ([Fig. 4B](#)). Negative correlations were observed between *IFIH1* and another independent signature for IPF (IPF-2; [Fig. 4D](#)) and with a signature of hypersensitivity pneumonitis (HP; [Fig. 4D](#)).

All these correlative patterns generally held true when rigorously tested across independent PBMC datasets from diverse patient cohorts, representing COVID-19 ([Fig. 4E and F](#)) and other viral respiratory pandemics ([Supplementary Figure S1](#)). *IFIH1* induction consistently correlated with a type 1 IFN-centric immune response in MDA5 autoimmunity, but not with the immune response in IPF.

### Impact of severity, sex, steroids and *IFIH1* genotype on MDA5 (*IFIH1*) surge

A subanalysis on the largest PBMC dataset that included information on sex and disease severity revealed that *IFIH1*, anti-MDA5-ILD and ViP signatures were induced in less severe disease which did not warrant ICU-level of care ([Fig. 4G](#)), whereas the 52-gene risk signature for progressive IPF was induced in more severe COVID-19 that required ICU care ([Fig. 4G](#)); these observations held true in both sexes.

Next we created a multivariate model to decompose the covariance between the levels of induction of *IFIH1* (base variable), genotype, sex, age, severity of ARDS; as determined using the ratio of *PaO2*/*FiO2*) and the need for ventilation (Vent). The *IFIH1* rs1990760 genotype



**Fig. 3: IFIH1 and autoimmune ILD gene signatures are induced in diverse cell types in CoV lung, including the alveolar epithelium. A.** Schematic showing the study design for panels A–B. **B.** Bubble plot of ROC-AUC values (radii of circles are based on the ROC-AUC) demonstrating the direction of gene regulation (Up, red; Down, blue) for the classification of various cell types between healthy and CoV lung based on various gene signatures in Fig. 3A, which includes several signatures of AT2 cytopathies that are encountered and implicated in ILD. Numbers

emerged as the strongest determinant of the degree of induction of the *IFIH1*(MDA5) transcript (Fig. 5A-left). Age emerged as an independent variable when the rs1990760 TT variant was analyzed independently (Fig. 5A-middle); young age was associated with higher levels of induction of *IFIH1* transcripts. Sex and the need for ventilation were covariates when the rs1990760 CT/CC variants were analyzed independently (Fig. 5A-right); females and moderate disease not requiring ventilator support was associated with a higher level of *IFIH1* transcript surge.

A similar analysis on another independent dataset in which intervention was performed in the form of systemic corticosteroid treatment. Such treatment is an independent protective factor exclusively in the subjects with rs1990760 CT/CC variants, but not in those with the rs1990760 TT variant (Fig. 5B). Taken together, these findings reveal a complex interplay between *IFIH1* genotype in which the rs1990760 TT variant offers age-dependent protection to the elderly. Among those who lack this protective variant, female and less severe disease increases the degree of *IFIH1* surge, whereas systemic therapy with steroids offers protection.

#### The nature of the immunophenotype associated with the induction of MDA5 (*IFIH1*) transcript

We asked if *IFIH1* induction may be associated with an age-dependent immunophenotype that modulates the risk of progressive autoimmune ILD. We assessed the differentially expressed genes (DEGs) between the two distinct groups of patients within the rs1990760 TT variant, i.e., low- and high-inducers of the *IFIH1* transcript (Fig. 5C and D). The *IFIH1*-high group induced 26 genes that are enriched for type 1 IFN signals and cellular responses to the same (Fig. 5E and F). Up-regulated genes are notable for markers of progressive autoimmune ILD, e.g., *CXCL10*,<sup>50</sup> IFN-induced genes associated with SARDs [*IFI44L*, *LY6E*, *OAS3*, *RSAD2*<sup>51</sup>], adaptive immune hallmarks of MDA5+ DM [*IFI6*, *MX1*, *OAS2*<sup>52</sup>] and *MX1*<sup>52</sup> (Fig. 5F). These DEGs were significantly induced in autoimmune ILD (Fig. 5G; non-specific interstitial pneumonitis, NSIP), compared to

IPF (usual interstitial pneumonia, UIP). Similarly, when we analyzed the DEGs in lung epithelial cells that were treated with acute vs convalescent serum derived exosomes, we found that the Type 1-centric genes induced in the lung epithelium were significantly induced also in NSIP compared to IPF (Supplementary Figure S2).

#### Discussion


Several COVID-19 era case reports or series of MDA5+ myositis or ILD have been reported in the UK and internationally either in the setting of infection or post-vaccination.<sup>2-5,15-32</sup> Our study is the largest one to document the features and outcomes of this clinical syndrome, especially in 2021. Approximately 42% of our MDA5+ cases have thus far have progressive ILD, with a third of these proving fatal so far, in keeping with the known aggressive course of MDA5+ILD.<sup>33,54</sup> Our clinical epidemiologic observations, together with the transcriptomic analyses suggest that increased incidence of MDA5 autoimmunity and ILD that presented contemporaneously during COVID-19 could be due to an aberrant type 1-centric IFN responses that are shared with autoimmune ILD, but not IPF, which plays out across diverse cell types leading to severe ILD (Fig. 6).

Our observations, taken together with global reports of similar cases, leads us to propose the term MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with the COVID-19 Pandemic (MIP-C) (Table 2). Such an acronym has credence because of the distinct features that separate MIP-C from the syndrome of adult MDA5+ DM<sup>57</sup> including our population being predominantly Caucasian instead of the historically reported MDA5+DM East Asian predilection and the lower rate of ILD that was evident in 42% of cases, at least thus far, to that historically reported in MDA5+DM.<sup>58-60</sup> Also the pathogenesis of MDA5+DM is poorly understood but our work in 60 new cases and that from around the world<sup>2-5,19,21,25,61-74</sup> shows good evidence for a link to SARS-CoV-2 infection and vaccination and possibly both (Fig. 2).

The MIP-C phenotype, somewhat akin to MIS-C in children, quite often had no history of confirmed SARS-

---

indicate PMIDs. Welch's two sample (H vs CoV) unpaired t-test is performed on the composite gene signature score (z-score of normalized tpm count) to compute the p values [\* . p ≤ 0.05; \*\* . p ≤ 0.01; \*\*\* . p ≤ 0.001]. **C and D.** Schematic summarizes the study design for GSE174668. Panel C shows the natural course of COVID-19 which includes pre-symptomatic (S1), hyperinflammatory (S2), resolution (S3) and convalescent (S4) phases. Typically, S1-2 is SARS-CoV-2 RNA positive and has mixed inflammation and immunosuppression as host immune response to the virus. The second half (S3-4) is characterized by host immune response that is geared towards resolution of inflammation and restoration of homeostasis. Exosome-enriched EVs were isolated from fasting plasma from healthy controls and COVID-19 patients from and then applied on two cell types (Panel D) for 12 h at 37 °C prior to RNA Seq analysis. **E and F:** Bubble plot of ROC-AUC values (radii of circles are based on the ROC-AUC) demonstrating the direction of gene regulation (Up, red; Down, blue) for the classification of cells treated with EVs from healthy controls vs those isolated from the indicated phase of CoV infection (S1-4) based on various gene signatures in Fig. 3A, which includes several signatures of AT2 cytopathies that are encountered and implicated in ILD. Numbers indicate PMIDs. Welch's two sample (H vs CoV) unpaired t-test is performed on the composite gene signature score (z-score of normalized tpm count) to compute the p values [\* . p ≤ 0.05; \*\* . p ≤ 0.01]. BALF, bronchoalveolar lavage fluid; H, healthy; CoV, COVID-19; AT2, alveolar type 2 pneumocytes; DATP, damage-associated transient progenitors; SSC, Systemic scleroderma; Sen, senescence.



**Fig. 4: Induction of *IFIH1* in COVID-19 correlates with a Type 1-IFN storm and anti-MDA5-ILD risk signatures in PBMCs.** **A.** Schematic of the workflow in this figure, indicating the types of samples analysed and the gene expression signatures tested. **B** and **C.** Scatter plots show the relationships between *IFIH1* expression (Y axis) and the composite scores of four different gene expression signatures (X axis) in PBMCs from

CoV-2 infection. Given that nearly 42% of new cases were not vaccinated prior to MDA5+ disease, it suggests that milder COVID-19 disease, either overt, or covert (i.e., asymptomatic infection or incidental exposure) may be sufficient to cause MDA5 autoimmunity. Given the peak of MDA5 positivity testing followed the peak of COVID-19 cases in 2021, and coincided with the peak of vaccination, these findings suggest an immune reaction or autoimmunity against MDA5 upon SARS-CoV-2 and/or vaccine exposure; it could represent novel immunogenicity in non-immune subjects upon RNA engagement with MDA5, causing a surge of cytokine response, and then the triggering of an autoimmune disease. The development of herd immunity and less respiratory exposure to SARS-CoV2 could theoretically contribute to the milder phenotype at the population level in our proposed MIP-C entity.

As for how COVID-19 vaccine may give rise to such immunogenicity, a recent study by Li et al., has shed some light.<sup>75</sup> The authors showed that in the lymph nodes (LNs), modified RNA sensed by MDA-5 results in the production of type I interferons (IFNs); the latter induce antigen-specific CD8+ T cell responses.<sup>75</sup> This conclusion was derived after the authors systematically evaluated the immunogenicity response to BNT162b2 LNP-mRNA against COVID-19 in numerous murine models lacking RNA-sensing pattern recognition receptors [Toll-like receptors 2, 3, 4, 5 and 7 and other inflammasome and necroptosis/pyroptosis pathways] where only MDA-5 was deemed important for type I interferon responses and for antigen-specific CD8+ T cell responses.<sup>75</sup> Because RNA can be recognized by MDA5 in a sequence and structure-dependent manner,<sup>76</sup> the resultant activation of the innate immune system is believed to be cell, tissue and context specific. Our finding incriminate MDA5 protein activation, whether linked to natural infection, or vaccination or potentially both as a trigger for MIP-C and that MDA5-mediated sensing (and mounting of an immunophenotype that is comprised of type 1 interferonopathy and antigen-specific CD8+ T cell responses; elaborated below) is a distinct trigger in MIP-C.

There are four noteworthy findings that inform how we recognize and/or manage MIP-C in the aftermath of


COVID-19. First, that the viral sensor *IFIH1*/MDA5 is induced in COVID-19 has been reported exhaustively.<sup>14,77–84</sup> We found that the severity of COVID-19 may dictate the risk of progression to ILDs of distinct immunopathogenesis: Milder disease induced *IFIH1* and risk signatures for MDA5-autoimmunity; however, severe disease with diffuse alveolar damage in the setting of acute respiratory distress syndrome (ARDS) induced risk signatures for alveolar dysfunction that are pathognomonic of IPF, consistent with prior claims.<sup>35</sup>

Second, it is noteworthy that the degree of *IFIH1* induction is strongly associated with the degree of induction of a type 1 IFN signature; the later is quite specific for being IL-15-centric [ViP signature<sup>40</sup>]. This finding is in keeping with prior work showing the importance of this IL-15 in rapidly progressing ILD in the setting of MDA5 autoimmunity and amyopathic DM.<sup>85–87</sup> Given the extensive literature on the role of the IL15/IL-15RA axis in the development of autoimmunity [reviewed in<sup>88</sup>], and more specifically its role in triggering the activation of CD8+ T cells to drive such autoimmunity.<sup>89–92</sup>

Third, the recognition of MIP-C as a syndrome where less than half of cases get severe progressive ILD is relevant for therapy selection including Janus kinase (JAK) inhibitors, such as tofacitinib<sup>93</sup> as many cases did not progress, at least in the first two years of MDA5+ status. Fourth, we show that the rs1990760 (p.Ala946Thr) *IFIH1* variant displays, what is likely to be an age-dependent protection,<sup>84</sup> to a subgroup of patients; these patients show a lesser induction of *IFIH1*, a blunted type 1 IFN storm, and a reduced signature of circulating *ISG15*+CD8+T cells which was previously found to predict poor one-year survival in MDA5+DM patients.<sup>47</sup>

Our study has some limitations, including the retrospective nature of the clinical data collection and uncertainties around the confirmation of COVID-19 infection status (most patients were not systematically tested) and could be infected but asymptomatic. Another limitation is the lack of data on Covid-19 serology, i.e., antibodies against spike, receptor binding domain of spike, and nucleoprotein. This limits any extrapolations in relationship to MIP-C disease and precise link

patients with COVID-19. Top panels in B show all three rs1990760 variant types. Bottom panels in C show just the TT variant. Interrupted lines are drawn arbitrarily to divide the graph into quadrants with low–low and high–high distributions to separate the patients who suppressed *IFIH1* in the TT genotype from those who did not. D. Graphical representation of a correlation matrix representing the correlation between the variables in B–C and additional variables, i.e., composite scores of different gene signatures elaborated in panel A. The colour key spans from –1 (magenta) to 1 (green), indicating both strength and direction of correlation. Numbers within the heatmap indicate statistical significance (only significant p values are displayed). E and F. Correlation matrix showing the correlation between multiple gene signatures (as in D), on two other independent COVID-19 (CoV) patient-derived PBMC datasets. See [Supplementary Figure S2](#) for similar analyses on three independent PBMC and whole blood datasets representing other respiratory viral pandemics. G. Violin plots show the degree of induction of *IFIH1* (transcripts per million; tpm) and various gene expression signature (composite scores) in male or female patients presenting with moderate (non-ICU) or severe (ICU) COVID-19. Welch's two sample (ICU vs non-ICU) unpaired t-test is performed on the tpm (for *IFIH1*) or the composite gene signature score (z-score of normalized tpm count) to compute the p values (only significant p values are displayed). The shaded region indicates the 95% confidence interval around the regression line.




**Fig. 5: The rs1990760 TT variant of *IFIH1* offers an age-dependent protection against MDA5 surge.** **A** and **B**. Multivariate analysis of *IFIH1* expression as a linear combination of all variables in the COVID-19 PBMC datasets GSE233626 (n = 42) (**A**) and GSE233627 (n = 21) (**B**). Coefficient of each variable (at the center) with 95% confidence intervals (as error bars) and the p values were illustrated in the bar plot. The p-value for each term tests the null hypothesis that the coefficient is equal to zero (no effect). Red = significant co-variables. **C–E**. Two distinct subgroups of COVID-19 patients with the rs1990760 TT genotype (groups 1 and 2 in the scatter plot in **A**) were assessed for differentially expressed genes (DEGs; **B**). Lollipop graph (**C**) displays the findings of a gene ontology (GO) analysis on the list of 26 genes upregulated in group 2. **F**. Heatmap displays DEGs (26 up- and 3 down-regulated; LogFC > 2, pAdj < 0.05) in group 2 PBMCs compared to group 1. **G**. Violin plots display the composite score of the DEGs (used as a gene signature) in two independent transcriptomic datasets of lung tissues from subjects with undefined (UIP) or non-specific (NSIP) interstitial pneumonitis and non-diseased controls.

between SARS-CoV-2 circulation, infection and vaccination. Furthermore, we have no data on asymptomatic infection or prolonged carriage status as potential factors in some of these cases; neither did we have patient-derived samples to analyse transcriptomic datasets from our cohort. Although key conclusions are

supported by multivariate analyses and correlation plots, which allow comparisons across groups, such statistical rigor was not possible in a few instances due to limitations in the available datasets (small sample size or insufficiently annotated for variables). Future studies on larger datasets, as and when they become available,





**Fig. 6: Summary and working model.** Schematic summarizes major conclusions and a proposed working model. A type 1-centric interferon response to the same could serve as pathophysiologic driver of autoimmune ILD involving more than one cell type. From left to right (Top): (i) In the alveolar pneumocytes of COVID-19 lungs, MDA5 is induced and is associated with type 1 interferon response, AT2 senescence and stem cell dysfunction. MDA5 is induced also in lung epithelial cells upon exposure to exosome vesicles from patients with acute infection. (ii) In the PBMCs of COVID-19 patients MDA5 is induced in infected samples, and its degree of induction positively and tightly correlates with an IL-15 centric type 1 interferon response. (iii) In the PBMCs of COVID-19 patients, there is a concomitant induction of a signature for anti-MDA5 autoimmune ILD expressed in ISG15+ CD8+ T cells. Bottom panel shows the impact of a protective genotype of the *IFIH1* gene which inhibits a subset of patients from inducing MDA5 and thereby protects them from a surge of type 1 interferon storm.

could help strengthen these observations. We also do not delineate how autoimmunity arises; given that MDA5 is a key RNA receptor in the lung parenchymal and immune cells it is tempting to speculate that MDA5 and nucleic acid as an antigen and associated bound

adjuvant could contribute to triggering autoimmunity. A clear mechanism for the vascular basis for the DM and PSS lesions is yet to emerge. Regardless, we have shown in numerous independent cohorts that the degree of induction of *IFIH1* (MDA5) is tightly correlated with the

	Classic MDA5 <sup>+</sup> -Disease	MIP-C
Age	Adults 7% MDA5 <sup>+</sup> among cases of juvenile dermatomyositis <sup>55,56</sup>	4/60 cases (6.6%) children
Sex	Females 66% <sup>57</sup>	36/60 cases (60%) females
Ethnic background	Asian	32/60 cases (53%) white (British or any other "white" category) <sup>a</sup>
Lung involvement	Almost universal in people of Asian descent. Pulmonary involvement reported between 39% and 73% elsewhere globally (Brazil, Italy, Spain, North America) <sup>44</sup>	25/60 cases (41.6 thus far)
Interstitial lung disease prognosis	Poor, frequently fatal in adults	Fatalities less common, though progressive pulmonary function deterioration frequent (8/60–13.3%)
Isolated, non-pulmonary disease	Uncommon	35/60 cases (58.3%) experienced manifestations of connective tissue diseases (18/60 cutaneous rash; 20/60 Raynaud's phenomenon; 5/60 "mechanic's hands", some of the 35 have more than one combined)
Associated antibody positivity		About two third cases have associated antibody positivity (36/60), being anti Ro 52 (13/60) and Anti SAE1 (12/60) the most common.

In the Yorkshire region of UK, the estimate for population classified as "white" (any "white" category) was 85.4%, according to 2021 UK census. Such percentage reflects the difference in prevalence recorded for the whole England and Wales population (81.7%) at the time of 2021 UK census. <sup>a</sup>14/60 patients had no ethnicity available.

**Table 2: Comparison between "classic" MDA5+ disease and MIP-C.**

degree of induction of type 1 interferons and a gene signature for risk of progressive MDA5<sup>+</sup>ILD.

In conclusion, in this work we report a remarkable rise in MDA5<sup>+</sup> disease in the Yorkshire region that, given the overall epidemiology, we have termed MIP-C. We provide transcriptome derived insights that point to a plausible and potentially causal link between the surge in anti-MDA5-positivity, autoimmune ILD and COVID-19, but not IPF. These findings warrant further studies, preferably through multi-centre efforts and across nations, to begin to recognize and better appreciate the potential global clinical burden of interstitial pneumonitis and ILD in the aftermath of the COVID-19 pandemic.

#### Contributors

SS conducted all the statistical, mathematical, computational, or other formal techniques; ST and EM assisted with dataset processing and curation; KI PD and GDM created all Tables for visualization and data presentation; SS and PG created all figures for visualization and data presentation; DMG conceptualized and supervised all clinical aspects of this study; PG conceptualized and supervised all computational aspects of this study; DM and PG jointly administered the project and secured funding; KI, PD, GDM, DMG and PG wrote initial draft. DMG and P.G have accessed and verified the underlying data. All authors read and approved the final version of the manuscript.

#### Data sharing statement

All data produced in the present work are contained in the manuscript.

#### Declaration of interests

The authors declare that they have no financial conflict of interests for this study.

#### Acknowledgements

We thank Guillermo M Albaiceta (Hospital Universitario Central de Asturias, Oviedo, Spain) for access to demographic metadata on published datasets. This work was supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes of Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists. The views expressed are those of the author(s) and not influenced by the study funders, the NHS, the NIHR or the Department of Health.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.ebiom.2024.105136>.

#### References

- Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. *Clin Immunol Immunopathol*. 1976;5:12–20. [https://doi.org/10.1016/0090-1229\(76\)90145-8](https://doi.org/10.1016/0090-1229(76)90145-8).
- Astorri D, Nalotto L, Vaccaro E, et al. AB0715 anti-MDA5 dermatomyositis after BNT162b2 vaccination. *Ann Rheum Dis*. 2022;81:1484. <https://doi.org/10.1136/annrheumdis-2022-eular.3988>.
- Gonzalez D, Gupta L, Murthy V, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. *Rheumatol Int*. 2022;42:1629–1641. <https://doi.org/10.1007/s00296-022-05149-6>.
- Kitajima T, Funauchi A, Nakajima T, Marumo S, Imura Y, Fukui M. Antimelanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines. *J Rheumatol*. 2022;49:1158–1162. <https://doi.org/10.3899/jrheum.220259>.
- Sugimoto T, Yorishima A, Oka N, et al. Appearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination. *Mod Rheumatol Case Rep*. 2023;7:108–112. <https://doi.org/10.1093/mrcr/rxac064>.
- McHugh NJ, Tansley SL. Autoantibodies in myositis. *Nat Rev Rheumatol*. 2018;14:290–302. <https://doi.org/10.1038/nrrheum.2018.56>.
- Alenzi FM. Myositis specific autoantibodies: a clinical perspective. *Open Access Rheumatol*. 2020;12:9–14. <https://doi.org/10.2147/OARRR.S231195>.
- Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. *Rheumatology*. 2010;49:433–440. <https://doi.org/10.1093/rheumatology/kep375>.
- Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. *J Am Acad Dermatol*. 2011;65:25–34. <https://doi.org/10.1016/j.jaad.2010.09.016>.
- Chen X, Zhang L, Jin Q, et al. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients. *Front Immunol*. 2022;13:987841. <https://doi.org/10.3389/fimmu.2022.987841>.
- Sakamoto N, Ishimoto H, Nakashima S, et al. Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis. *Intern Med*. 2019;58:837–841. <https://doi.org/10.2169/internalmedicine.1516-18>.
- Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. *Arthritis Rheum*. 2009;60:2193–2200. <https://doi.org/10.1002/art.24621>.
- Yamada T, Sato S, Sotoyama Y, et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. *Nat Immunol*. 2021;22:820–828. <https://doi.org/10.1038/s41590-021-00942-0>.
- Amado-Rodríguez L, Salgado Del Riego E, Gomez de Ona J, et al. Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study. *Elife*. 2022;11. <https://doi.org/10.7554/eLife.73012>.
- Wang G, Wang Q, Wang Y, et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. *Front Immunol*. 2021;12:791348. <https://doi.org/10.3389/fimmu.2021.791348>.
- Swartzman I, Gu JJ, Toner Z, Grover R, Suresh L, Ullman LE. Prevalence of myositis-specific autoantibodies and myositis-associated autoantibodies in COVID-19 patients: a pilot study and literature review. *Cureus*. 2022;14:e29752. <https://doi.org/10.7759/cureus.29752>.
- Aschman T, Schneider J, Greuel S, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. *JAMA Neurol*. 2021;78:948–960. <https://doi.org/10.1001/jamaneurol.2021.2004>.
- Anderle K, Machold K, Kiener HP, et al. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. *BMC Rheumatol*. 2022;6:42. <https://doi.org/10.1186/s41927-022-00271-1>.
- Wang S, Noumi B, Malik F, Wang S. A rare case of MDA-5-positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease following COVID-19 mRNA vaccination - a case report. *SN Compr Clin Med*. 2023;5:18. <https://doi.org/10.1007/s42399-022-01357-0>.
- Maezawa Y, Narita M, Tanimura R, Hattori S, Satoh H. Rapidly progressive interstitial lung disease associated with melanoma differentiation-associated gene 5 antibody. *Acta Med*. 2022;65:37–40. <https://doi.org/10.14712/18059694.2022.15>.
- Takahashi S, Kato A, Hashimoto K, Takehara T, Ishioka K, Takanashi S. A case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung diseases developed after administration of COVID-19 vaccine and subsequent pneumococcal vaccine. *Respirol Case Rep*. 2022;10:e01064. <https://doi.org/10.1002/rcr2.1064>.
- Teo K-F, Chen D-Y, Hsu J-T, et al. Screening and characterization of myositis-related autoantibodies in COVID-19 patients. *Clin Transl Sci*. 2023;16:140–150. <https://doi.org/10.1111/cts.13434>.

- 23 Cao Y, Zhou J, Cao T, Zhang G, Pan H. Management of dermatomyositis patients amidst the COVID-19 pandemic: two case reports. *Medicine*. 2022;101:e30634. <https://doi.org/10.1097/MD.00000000000030634>.
- 24 Bobirca A, Alexandru C, Musetescu AE, et al. Anti-MDA5 amyopathic dermatomyositis-A diagnostic and therapeutic challenge. *Life*. 2022;12. <https://doi.org/10.3390/life12081108>.
- 25 García-Bravo L, Calle-Rubio M, Fernández-Arquero M, et al. Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies. *J Transl Autoimmun*. 2022;5:100160. <https://doi.org/10.1016/j.jtauto.2022.100160>.
- 26 Mecoli CA, Yoshida A, Paik JJ, et al. Presence and implications of anti-angiotensin converting enzyme-2 immunoglobulin M antibodies in anti-melanoma-differentiation-associated 5 dermatomyositis. *ACR Open Rheumatol*. 2022;4:457–463. <https://doi.org/10.1002/acr2.11423>.
- 27 Gupta P, Kharbanda R, Lawrence A, Gupta L. Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic. *Egypt Rheumatol*. 2021;43:271–274. <https://doi.org/10.1016/j.ejr.2021.06.001>.
- 28 De Santis M, Isailovic N, Motta F, et al. Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies. *Curr Opin Rheumatol*. 2021;33:514–521. <https://doi.org/10.1097/BOR.0000000000000844>.
- 29 Kondo Y, Kaneko Y, Takei H, et al. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still's disease. *Clin Exp Rheumatol*. 2021;39:631–638. <https://doi.org/10.55563/clinexprheumatol/44kaji>.
- 30 Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, et al. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. *Mod Rheumatol Case Rep*. 2021;5:101–107. <https://doi.org/10.1080/24725625.2020.1832755>.
- 31 Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. *Rheumatology*. 2012;51:1563–1570. <https://doi.org/10.1093/rheumatology/kes102>.
- 32 Wang Y, Du G, Zhang G, Matucci-Cerinic M, Furst DE. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. *Ann Rheum Dis*. 2022;81:e192. <https://doi.org/10.1136/annrheumdis-2020-218594>.
- 33 *NHS spine*; 2023. <https://digital.nhs.uk/services/spine>.
- 34 Lackner A, Tiefenthaler V, Mirzayeva J, et al. The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. *Ther Adv Musculoskelet Dis*. 2020;12:1759720X20975907. <https://doi.org/10.1177/1759720X20975907>.
- 35 Sinha S, Castillo V, Espinoza CR, et al. COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis. *eBioMedicine*. 2022;82:104185. <https://doi.org/10.1016/j.ebiom.2022.104185>.
- 36 Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. *J Clin Invest*. 2012;122:2756–2762. <https://doi.org/10.1172/JCI60323>.
- 37 Sahoo D, Dill DL, Tibshirani R, Plevritis SK. Extracting binary signals from microarray time-course data. *Nucleic Acids Res*. 2007;35:3705–3712. <https://doi.org/10.1093/nar/gkm284>.
- 38 *EsriUKContent. Census 2021. Ethnic group (detailed) for England and Wales for a selection of administrative and census areas*. 2021.
- 39 Decker P, Moulinet T, Lopez B, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. *Eur J Intern Med*. 2021;91:45–52. <https://doi.org/10.1016/j.ejim.2021.04.020>.
- 40 Sahoo D, Katkar GD, Khandelwal S, et al. AI-guided discovery of the invariant host response to viral pandemics. *eBioMedicine*. 2021;68:103390. <https://doi.org/10.1016/j.ebiom.2021.103390>.
- 41 Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. *N Engl J Med*. 2020;383:120–128. <https://doi.org/10.1056/NEJMoa2015432>.
- 42 Choi J, Park J-E, Tsagkogeorga G, et al. Inflammatory signals induce AT2 cell-derived damage-associated transient progenitors that mediate alveolar regeneration. *Cell Stem Cell*. 2020;27:366–382. <https://doi.org/10.1016/j.stem.2020.06.020>.
- 43 Kobayashi Y, Tata A, Konkimalla A, et al. Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis. *Nat Cell Biol*. 2020;22:934–946. <https://doi.org/10.1038/s41556-020-0542-8>.
- 44 Strunz M, Simon LM, Ansari M, et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. *Nat Commun*. 2020;11:3559. <https://doi.org/10.1038/s41467-020-17358-3>.
- 45 Yao C, Guan X, Carraro G, et al. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. *Am J Respir Crit Care Med*. 2021;203:707–717. <https://doi.org/10.1164/rccm.202004-1274OC>.
- 46 Ju Z, Jiang H, Jaworski M, et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. *Nat Med*. 2007;13:742–747. <https://doi.org/10.1038/nm1578>.
- 47 Ye Y, Chen Z, Jiang S, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. *Nat Commun*. 2022;13:6458. <https://doi.org/10.1038/s41467-022-34145-4>.
- 48 Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. *Sci Transl Med*. 2013;5:205ra136. <https://doi.org/10.1126/scitranslmed.3005964>.
- 49 Herazo-Maya JD, Sun J, Molyneux PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. *Lancet Respir Med*. 2017;5:857–868. [https://doi.org/10.1016/S2213-2600\(17\)30349-1](https://doi.org/10.1016/S2213-2600(17)30349-1).
- 50 Kameda M, Otsuka M, Chiba H, et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases—associated interstitial lung disease and interstitial pneumonia with autoimmune features. *PLoS One*. 2020;15:e0241719. <https://doi.org/10.1371/journal.pone.0241719>.
- 51 Baglaenko Y, Chang N-H, Johnson SR, et al. The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease. *Arthritis Res Ther*. 2018;20:264. <https://doi.org/10.1186/s13075-018-1752-3>.
- 52 Hamano Y, Kida H, Ihara S, et al. Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. *Sci Rep*. 2017;7:43201. <https://doi.org/10.1038/srep43201>.
- 53 Wang H, Chen X, Du Y, et al. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. *Arthritis Res Ther*. 2023;25:127. <https://doi.org/10.1186/s13075-023-03100-z>.
- 54 So J, So H, Wong V-T, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. *Rheumatology*. 2022;61:4437–4444. <https://doi.org/10.1093/rheumatology/keac094>.
- 55 Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. *Arthritis Res Ther*. 2014;16:R138. <https://doi.org/10.1186/ar4600>.
- 56 Mamyrova G, Kishi T, Shi M, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. *Rheumatology*. 2021;60:1839–1849. <https://doi.org/10.1093/rheumatology/keaa429>.
- 57 Wu W, Guo L, Fu Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. *Clin Rev Allergy Immunol*. 2021;60:293–304. <https://doi.org/10.1007/s12016-020-08822-5>.
- 58 Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. *Arthritis Care Res*. 2015;67:667–672. <https://doi.org/10.1002/acr.22498>.
- 59 Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. *Arthritis Rheum*. 2005;52:1571–1576. <https://doi.org/10.1002/art.21023>.
- 60 Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. *Front Immunol*. 2021;12:773352. <https://doi.org/10.3389/fimmu.2021.773352>.
- 61 De Marco G, Gyryes S, Williams K, et al. A large cluster of new onset autoimmune myositis in the Yorkshire region following

- SARS-CoV-2 vaccination. *Vaccines (Basel)*. 2022;10. <https://doi.org/10.3390/vaccines10081184>.
- 62 Camargo-Coronel A, Quiñones-Moya H, Hernández-Zavala MR, Hernández-Vázquez JR, Vázquez-Zaragoza MÁ. Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review. *Reumatismo*. 2023;75. <https://doi.org/10.4081/reumatismo.2023.1548>.
  - 63 Syrmou V, Liaskos C, Ntavari N, et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. *Immunol Res*. 2023;71:537–546. <https://doi.org/10.1007/s12026-023-09368-2>.
  - 64 Rimmer S, Ly L, Boh E. Subacute cutaneous lupus erythematosus after mRNA-based SARS-CoV-2 vaccination. *JAAD Case Rep*. 2023;33:70–72. <https://doi.org/10.1016/j.jidcr.2023.01.013>.
  - 65 Chan AR, Cohen Tervaert JW, Redmond D, et al. A case series of dermatomyositis following SARS-CoV-2 vaccination. *Front Med*. 2022;9:1013378. <https://doi.org/10.3389/fmed.2022.1013378>.
  - 66 Ding Y, Ge Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. *Front Public Health*. 2022;10:1007637. <https://doi.org/10.3389/fpubh.2022.1007637>.
  - 67 Yang L, Ye T, Liu H, Huang C, Tian W, Cai Y. A case of Anti-MDA5-Positive dermatomyositis after inactivated COVID-19 vaccine. *J Eur Acad Dermatol Venereol*. 2023;37:e127–e129. <https://doi.org/10.1111/jdv.18653>.
  - 68 Holzer M-T, Krusche M, Ruffer N, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. *Rheumatol Int*. 2022;42:2267–2276. <https://doi.org/10.1007/s00296-022-05176-3>.
  - 69 Chaima K, Mariem A, Sana B, et al. Vaccine-induced dermatomyositis following COVID-19 vaccination. *Dermatol Ther*. 2022;35:e15749. <https://doi.org/10.1111/dth.15749>.
  - 70 Gil-Vila A, Ravichandran N, Selva-O'Callaghan A, et al. COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: vaccine safety in idiopathic inflammatory myopathies. *Muscle Nerve*. 2022;66:426–437. <https://doi.org/10.1002/mus.27681>.
  - 71 Gouda W, Albasri A, Alsaqabi F, Al Sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. *J Korean Med Sci*. 2022;37:e32. <https://doi.org/10.3346/jkms.2022.37.e32>.
  - 72 Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis. *J Dtsch Dermatol Ges*. 2023;21:853–861. <https://doi.org/10.1111/ddg.15114>.
  - 73 Lee AYS, Lee C, Brown DA, Suan D. Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination. *Postgrad Med J*. 2023;99:363–364. <https://doi.org/10.1136/postgradmedj-2022-141510>.
  - 74 Tada T, Murao H, Shiratani R, et al. Spontaneous resolution of inflammatory myopathy involving the masseter muscle following COVID-19 mRNA vaccination. *Mod Rheumatol Case Rep*. 2023;8:77–82. <https://doi.org/10.1093/mrcr/rxad022>.
  - 75 Li C, Lee A, Grigoryan L, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. *Nat Immunol*. 2022;23:543–555. <https://doi.org/10.1038/s41590-022-01163-9>.
  - 76 de Oliveira Mann CC, Hornung V. Molecular mechanisms of nonself nucleic acid recognition by the innate immune system. *Eur J Immunol*. 2021;51:1897–1910. <https://doi.org/10.1002/eji.202049116>.
  - 77 Thorne LG, Reuschl A-K, Zuliani-Alvarez L, et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. *EMBO J*. 2021;40:e107826. <https://doi.org/10.15252/embj.2021107826>.
  - 78 Liu G, Lee J-H, Parker ZM, et al. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. *Nat Microbiol*. 2021;6:467–478. <https://doi.org/10.1038/s41564-021-00884-1>.
  - 79 Han L, Zhuang M-W, Deng J, et al. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. *J Med Virol*. 2021;93:5376–5389. <https://doi.org/10.1002/jmv.27050>.
  - 80 Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. *Cell Rep*. 2021;34:108628. <https://doi.org/10.1016/j.celrep.2020.108628>.
  - 81 Sampaio NG, Chauveau L, Hertzog J, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. *Sci Rep*. 2021;11:13638. <https://doi.org/10.1038/s41598-021-92940-3>.
  - 82 Russ A, Wittmann S, Tsukamoto Y, et al. Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. *EMBO Rep*. 2022;23:e55648. <https://doi.org/10.15252/embr.202255648>.
  - 83 Rebendenne A, Valadão ALC, Tauziet M, et al. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. *J Virol*. 2021;95. <https://doi.org/10.1128/JVI.02415-20>.
  - 84 Muñiz-Banciella MG, Albaiceta GM, Amado-Rodríguez L, et al. Age-dependent effect of the IFIH1/MDA5 gene variants on the risk of critical COVID-19. *Immunogenetics*. 2023;75:91–98. <https://doi.org/10.1007/s00251-022-01281-6>.
  - 85 Takada T, Ohashi K, Hayashi M, et al. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. *Respir Med*. 2018;141:7–13. <https://doi.org/10.1016/j.rmed.2018.06.012>.
  - 86 Shimizu T, Koga T, Furukawa K, et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. *J Intern Med*. 2021;289:206–220. <https://doi.org/10.1111/joim.13154>.
  - 87 Hu H, Yang H, Liu Y, Yan B. Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. *Front Med*. 2021;8:833114. <https://doi.org/10.3389/fmed.2021.833114>.
  - 88 Allard-Chamard H, Mishra HK, Nandi M, et al. Interleukin-15 in autoimmunity. *Cytokine*. 2020;136:155258. <https://doi.org/10.1016/j.cyto.2020.155258>.
  - 89 Li J, Zaslavsky M, Su Y, et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. *Science*. 2022;376:eabi9591. <https://doi.org/10.1126/science.abi9591>.
  - 90 Watkinson F, Nayar SK, Rani A, et al. IL-15 upregulates telomerase expression and potentially increases proliferative capacity of NK, NKT-like, and CD8 T cells. *Front Immunol*. 2020;11:594620. <https://doi.org/10.3389/fimmu.2020.594620>.
  - 91 Schluns KS, Anthony S. Emerging roles for IL-15 in the activation and function of T-cells during immune stimulation. *Res Rep Biol*. 2015;25. <https://doi.org/10.2147/RRB.S57685>.
  - 92 Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. *Nat Immunol*. 2021;22:809–819. <https://doi.org/10.1038/s41590-021-00949-7>.
  - 93 Selva-O'Callaghan A, Romero-Bueno F, Trallero-Araguás E, et al. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. *Curr Treatm Opt Rheumatol*. 2021;7:319–333. <https://doi.org/10.1007/s40674-021-00186-x>.